Division of Infectious Diseases, Washington University in St Louis, USA.
Global AMR Research and Development Hub Secretariat, Germany.
Curr Opin Microbiol. 2020 Oct;57:56-61. doi: 10.1016/j.mib.2020.06.009. Epub 2020 Aug 7.
Antimicrobial resistance (AMR) is an urgent public health threat, and continues to be on the rise. Basic microbiological research is the foundation for addressing knowledge gaps both for the development of new antibiotics, diagnostics and preventives but also to inform strategies to mitigate the transmission of resistance and drug resistant microorganisms. Translating this research into new products to reinvigorate dwindling pipelines, especially for new antibiotics, is one of the main challenges faced in addressing AMR. The scientific complexity is compounded by the market uncertainty of any new products leading to a large proportion of pharmaceutical companies exiting the market. Consequently, a number of initiatives were developed to reinvigorate the AMR research and development (R&D) landscape. Despite all these efforts, the antibiotic pipeline remains inadequate to keep up with the increasing rates of resistance globally. Given the number of individual and multilateral actions, there is an urgent need for a common platform and coordination to ensure that resources are adequately used to address the critical challenges posed by AMR globally hence the founding of the Global AMR R&D Hub to take on this role.
抗菌药物耐药性（AMR）是一项紧迫的公共卫生威胁，且耐药性仍在不断上升。基础微生物学研究是解决知识空白的基础，这些知识空白既包括开发新抗生素、诊断方法和预防方法，也包括制定减轻耐药性和耐药微生物传播的策略。将这项研究转化为新产品，以重振日益枯竭的药物研发管线，特别是针对新抗生素，是应对 AMR 所面临的主要挑战之一。由于任何新产品的市场不确定性导致相当大比例的制药公司退出市场，因此科学的复杂性进一步加剧。因此，为了重振 AMR 研究和开发（R&D）格局，制定了多项举措。尽管做出了所有这些努力，但抗生素研发管线仍然不足以跟上全球耐药率的不断上升。鉴于采取了许多个人和多边行动，因此迫切需要一个共同的平台和协调，以确保资源得到充分利用，来应对全球 AMR 带来的严峻挑战，这就是成立全球 AMR R&D 中心的原因。
